Organisation paid for research Program year 2025 Source: CMS Open Payments

Sanchez Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,731,526

139 payments

Through program year 2025, Sanchez Clinical Research Inc is reported as receiving $1,731,526 in research payments, across 139 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $377,868 28
2024 Research $42,710 5
2023 Research $388,146 8
2022 Research $323,606 8
2021 Research $145,703 40
2020 Research $234,382 26
2019 Research $219,111 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $480,301 3 payments
  2. Allergan Inc. $426,457 39 payments
  3. Sanofi US Services Inc. $340,434 22 payments
  4. Eli Lilly and Company $183,572 11 payments
  5. Boehringer Ingelheim International GmbH $119,387 3 payments
  6. Shire North American Group Inc $52,500 15 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $44,119 3 payments
  8. AbbVie, Inc. $32,482 4 payments
  9. Boehringer Ingelheim RCV GmbH & Co KG $19,493 33 payments
  10. Madrigal Pharmaceuticals $18,780 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. POCC in NASH $619,181 39 payments
  2. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $236,063 14 payments
  3. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $183,772 11 payments
  4. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $132,003 1 payment
  5. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis $104,371 8 payments
  6. An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $43,219 3 payments
  7. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $39,433 2 payments
  8. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $39,359 2 payments
  9. A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh $34,609 8 payments
  10. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $30,454 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record